Caristo provides AI-powered cardiovascular diagnostic solutions for early detection and prevention of heart attacks.

Caristo

Caristo Diagnostics has been formed to bring revolutionary cardiovascular diagnostic tools to patients worldwide. Our proprietary technology transforms the accuracy of routine cardiac CT scans by extracting new information that is otherwise invisible, greatly enhancing the power to predict cardiovascular risk and refine treatment decisions.

Our Website: https://www.caristo.com

Follow us on Twitter: https://twitter.com/CaristoHeart

Longwall Venture Partners

Oxford Science Enterprises

Oxford Investment Consultants LLP

Caristo Diagnostics

We’re gearing up for #ESC2024 in London! 
📅 Save the Date: Join us at our satellite symposium to explore groundbreaking insights into coronary artery disease prevention through the lens of coronary inflammation. Learn more - https://lnkd.in/dkb8u5hu 

💬 Meet Us at ESC: Book a meeting at booth C600 to meet the Caristo Medical and Business team and discover our innovative CaRi-Heart Technology. 
Schedule a booth appointment - https://lnkd.in/e9FD6ZQm 

European Society of Cardiology, Prof Peter Libby, Prof John Deanfield CBE, Prof Ron Blankstein, Prof Charalambos Antoniades, Harvard Medical School, Brigham and Women's Hospital, University of Oxford

#Prevention #Cardiovasculardisease #heartattack #FAIScore #coronaryinflammation

We had an incredible symposium chaired by Prof. Peter Libby, Brigham and Women's Hospital and Harvard Medical School, and Prof. John Deanfield CBE, University College London, at #ESC2024. Highlights included excellent presentations from Prof. Ron Blankstein (Brigham and Women's Hospital and Harvard Medical School) and Prof. Charalambos Antoniades (University of Oxford) on the evolution of CAD diagnosis, shifting from stenosis to coronary inflammation, as measured by the FAI-Score. Thank you all for joining us. 

To learn more about the FAI-Score, visit us at the Caristo booth #C600! 

Discover more - https://lnkd.in/dZQb6927 
European Society of Cardiology #FAIScore #CoronaryInflammation #CardiovascularDisease #Prevention #HeartDisease #HeartAttackRisk

Caristo at #ESC2024 in London!  
💡 Attend our symposium to explore groundbreaking insights into coronary artery disease prevention through the lens of coronary inflammation.  
👉 Meet us at booth C600 to discover our innovative CaRi-Heart Technology. https://bit.ly/3VL3acQ 

#CoronaryInflammation #FAIScore #MedicalInnovation #Healthcare #Congress #Imaging

We were delighted to welcome Dr. Andrew Mitchell, Consultant Cardiologist at Jersey General Hospital and Honorary Consultant at Oxford University Hospitals NHS Foundation Trust, to our Oxford HQ this week. Our product, clinical, and business teams had engaging and productive discussions with him. We look forward to expanding access to CaRi-Heart, ensuring even more patients in the Channel Islands of Jersey benefit from our innovative solution. 

💡 Learn more about CaRi-Heart Technology on our website - https://lnkd.in/euTKa2im

#CoronaryInflammation #FAIScore #MedicalInnovation #Healthcare

We're #hiring a new Image Analyst in Oxfordshire, England. Apply today or share this post with your network.

Excellent news Dr Murray, having researched this technology, this is a game changer , moving to an absolute risk, as opposed to using existing models that can under estimate risk is essential given cardiovascular disease is the leading cause of mortality, looomg forward to our collaboration

msh id	COM:CARISTO
symbol	-
name	Caristo
homepage url	https://www.caristo.com
country	GB
sector	Healthcare & Health Services
industry	Medical Technology
market	PRIVATE
employee count	43
crunchbase url	-
linkedin url	https://www.linkedin.com/company/caristo
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

CARI

COM:CARISTO

Caristo

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-